Strategic Acquisition ZenBio was recently acquired by BioIVT, signaling a shift in capabilities and expanded global reach. This presents an opportunity to align offerings with BioIVT’s biospecimen solutions and leverage combined contracts, increasing value propositions for pharmaceutical and diagnostics customers.

Expanded Capabilities ZenBio specializes in adipose derived stem cells, primary human cell systems, and custom cell isolations from various tissues. This breadth can cross-sell with BioIVT’s existing services to provide end-to-end cell biology solutions for drug discovery and cosmetic research.

Midmarket Focus With 11-50 employees and annual revenue in the 10-25M range, ZenBio sits in a midmarket segment that benefits from streamlined, scalable contracts and rapid onboarding for CROs and pharma partners seeking specialized cell-based tools.

High-Value Niches The company’s emphasis on adipocytes, stem cells, hepatocytes, and custom tissue-derived cells positions it to address niche needs in toxicity testing, disease modeling, and cosmetic science, offering targeted upsell opportunities to customers requiring unique human cell systems.

Digital & Global Reach Existing tech stack includes Google tracking, CRM-friendly tools, and Microsoft 365, suggesting readiness for enhanced digital campaigns, partner enablement, and account-based marketing efforts to accelerate engagement with larger biotech and pharma buyers.